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Francisella tularensis Schu S4 Lipopolysaccharide Core Sugar and
O-Antigen Mutants Are Attenuated in a Mouse Model of Tularemia
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Bradley D. Jonesa,c,g
Department of Microbiology,a Department of Pathology,b and The Genetics Program,c University of Iowa Carver College of Medicine, Iowa City, Iowa, USA; Biological
Sciences Division/Microbiology, Pacific Northwest National Laboratory, Richland, Washington, USAd; The Buck Institute for Age Research, Novato, California, USAe; The
Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, USAf; Midwest Regional Center for Excellence in Biodefense and
Emerging Infectious Disease Research, Washington University, St. Louis, Missouri, USAg
The virulence factorsmediating Francisella pathogenesis are being investigated, with an emphasis on understanding how the or-
ganism evades innate immunity mechanisms. Francisella tularensis produces a lipopolysaccharide (LPS) that is essentially inert
and a polysaccharide capsule that helps the organism to evade detection by components of innate immunity. Using an F. tular-
ensis Schu S4mutant library, we identified strains that are disrupted for capsule and O-antigen production. These serum-sensi-
tive strains lack both capsule production and O-antigen laddering. Analysis of the predicted protein sequences for the disrupted
genes (FTT1236 and FTT1238c) revealed similarity to those forwaa (rfa) biosynthetic genes in other bacteria. Mass spectrometry
further revealed that these proteins are involved in LPS core sugar biosynthesis and the ligation of O antigen to the LPS core sug-
ars. The 50% lethal dose (LD50) values of these strains are increased 100- to 1,000-fold for mice. Histopathology revealed that the
immune response to the F. tularensismutant strains was significantly different from that observed with wild-type-infected mice.
The lung tissue frommutant-infected mice had widespread necrotic debris, but the spleens lacked necrosis and displayed neu-
trophilia. In contrast, the lungs of wild-type-infected mice had nominal necrosis, but the spleens had widespread necrosis. These
data indicate that murine death caused by wild-type strains occurs by a mechanism different from that by which the mutant
strains kill mice. Mice immunized with these mutant strains displayed>10-fold protective effects against virulent type A F. tula-
rensis challenge.
Francisella tularensis is a small Gram-negative bacterium thatcauses tularemia in humans. This bacterial pathogen causes
disease by diverse routes, including oral, intravenous, subcutane-
ous, and pneumonic routes; the respiratory route is of particular
concern, because infection with 10 or fewer organisms is associ-
ated with mortality rates of 30 to 60% if left untreated (1, 2). The
pathogen employs a virulence strategy in which it enters host cells,
escapes the phagosome, and grows within the cytosol of the cell,
apparently with diminished or delayed detection by host innate
defenses (3). The interplay of bacteria with host macrophages is a
significant focus of research efforts, as these interactions are crit-
ical to virulence (4). However, the organism also has important
interactions with other cells, including epithelial and endothelial
cells, hepatocytes, and neutrophils (5–9). Migration of infected
leukocytes throughout the vasculature leads to seeding of sites in
the lymphatic system, establishment of systemic disease, and,
eventually, death by multiple-organ failure (10). Due to the ex-
treme virulence and ease of aerosol dissemination of F. tularensis,
the U.S. Centers for Disease Control and Prevention have classi-
fied this organism as a tier 1 select agent because of its potential for
development into a bioweapon (11).
One important contributing factor to the high virulence of this
pathogen is that its intracellular growth appears to be relatively
unchecked because it fails to induce significant host immune re-
sponses (12). Lipid A of F. tularensis is highly unusual in that it is
asymmetrical and tetra-acylated and has long-chain fatty acids (16
to 18 carbons). In addition, the phosphate at the 1 position on the
diglucosamine backbone can be shielded by a galactosamine,
while a phosphate group at the 4= position of the sugar backbone
has not been observed (13–15). This is in contrast to the lipid A
structures of most Gram-negative bacteria, which contain six acyl
chains of 12 to 14 carbons and phosphate groups that are available
for interactions with Toll-like receptor 4 (TLR4), which can stim-
ulate a strong proinflammatory response (16–18). In comparison,
the endotoxin of F. tularensis does not bind to lipopolysaccharide-
binding protein (LBP) and therefore does not activate TLR4 sig-
naling pathways, rendering it inert compared to typical endotox-
ins (15, 19). Several research groups are working to understand
how acylation, the length of fatty acid side chains, and shielding of
the phosphates of the endotoxin contribute to the lack of bioac-
tivity of F. tularensis lipopolysaccharide (LPS). In addition, F. tu-
larensis LPS and capsule opsonize complement components that
aid in the uptake of the bacterium into host cells while simultane-
ously protecting the organism from the killing activity of comple-
ment (20). Each of these areas of immune evasion continues to be
an active area of research to understand the Francisella virulence
strategy.
Our research group is actively focusing on understanding how
the Francisella capsule contributes to the pathogenesis of this or-
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ganism. Work published in 1977 described a crude “capsular”
preparation that containedmannose, rhamnose, and dideoxy sug-
ars (21). Sandstrom et al. created an acapsular Francisella strain
and found that it was sensitive to antibody-mediated killing (22).
Recent work using a monoclonal antibody directed against puri-
fied capsularmaterial of Francisella has helped to characterize sev-
eral aspects of this capsule (23). The capsular material was shown
to range in size from 100 to 250 kDa, and the material could be
separated from LPS by selective Triton X-114 treatment. Further-
more, the capsule was detected in all type A and B strains of Fran-
cisella tularensis that were examined (23). Immunization of mice
with purified capsular material elicited circulating anti-capsule
antibodies in the mice that protected them from challenge with F.
tularensis LVS but did not protect from F. tularensis Schu S4 chal-
lenge (23). In this report, we extend our previous findings by
characterizing in more detail how the FTT1236 and FTT1238c
gene products participate in LPS core biosynthesis and examining
how these structures contribute to the virulence of this pathogen
in the murine host. Based on results presented here, we propose
the gene names waaY, waaZ, and waaL for the F. tularensis
FTT1236, FTT1237, and FTT1238c genes, respectively. We have
chosen to use the “waa” nomenclature with these genes because
the proteins produced are involved in LPS core biosynthesis as
well asO-antigen ligation to the core of the LPS (24).However, the
genes are not exact orthologues of the Escherichia coli or Salmo-
nella enterica genes, so the last letter of each gene name is unique to
Francisella to make this point. FTT1238c is the exception, in that
the Francisella protein appears to have the same role as WaaL
proteins in other organisms. Our data also demonstrate that these
mutant strains can evoke protection and a delay to death after
lethal Schu S4 challenge of mice.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Francisella tularensis subsp. tu-
larensis Schu S4 was routinely cultured on modified Mueller-Hinton
(MMH) plates (Acumedia, Lansing, MI) or in MMH broth. E. coli mu-
tants were acquired from the Keio collection (National Bioresource Proj-
ect, Japan), and the E. coli parent BW25113 was obtained from David
Weiss (University of Iowa). The Salmonella enterica serovar Typhimu-
rium SL1344 strain and E. coli strains were grown on L agar or in L broth
supplemented with either 50g kanamycin or 50g chloramphenicol, as
appropriate. All work with F. tularensis Schu S4 was performed within the
Carver College of Medicine Biosafety Level 3 (BSL3) Core Facility, and
experimental protocols were reviewed for safety by the BSL3 Oversight
Committee of The University of Iowa Carver College of Medicine. Re-
combinant DNA work with F. tularensis Schu S4 was reviewed and ap-
proved by the University of Iowa Institutional Biosafety Committee.
We constructed LVS 0708::TrgTn and LVS 0706::TrgTn mutants by
using previously constructed plasmids (25) and the Targetron system
(Sigma). These mutations appeared to have effects on the lipid A core
structures of the LVS mutants identical to those in the corresponding
Schu S4 FTT1236::TrgTn and Schu S4 FTT1238::TrgTnmutants. The LVS
mutant strains were used to purify sufficient quantities of LPS to deter-
mine the structures and compositions of the lipid A core structures.
Creation of a Tn5lacZ Francisella tularensis Schu S4mutant library.
Tn5lacZ insertions were generated by introducing the temperature-sensi-
tive transposon delivery plasmid pBB105 into Francisella tularensis Schu
S4 via cryotransformation (26). Transformed Francisella organisms were
selected on MMH plates containing kanamycin at 32°C to select for the
presence of pBB105. A single kanamycin-resistant colony was cultured in
2 ml of MMH broth with kanamycin and grown overnight at 32°C to an
optical density at 600 nm (OD600) of 1.1. The culture was serially di-
luted, plated onto chocolate agar, and grown at 40°C in 5% CO2 for 48 h
to cure the temperature-sensitive delivery plasmid and select for Tn5lacZ
chromosomal insertion mutants. Mutant colonies were picked, arrayed
into 96-well plates containing 100 l of MMH broth, and grown for 24 h
at 37°C with 5% CO2. Approximately 7,500 mutants were created and
isolated using this technique. Freezing mediumwas added to each well, at
a 1:1 ratio, and plates were stored at80°C for long-term storage.
Screening for F. tularensis Schu S4 capsule-deficient mutants by
ELISA. In preparation for screeningof the transposon library, eachmutant in
the 96-well plate library was transferred from themaster plate to a fresh plate
containing 200l ofMMHbroth per well. Plates were incubated at 37°C for
48 h. Plates were read by measuring the OD600 in a microplate autoreader
(Bio-Tek Instruments). A final concentration of 4% paraformaldehyde
(PFA) was used to simultaneously fix and kill the organisms in each well.
Wells were air dried to evaporate the broth-PFAmixture, and then each well
was washed with phosphate-buffered saline (PBS) and blocked with 1% bo-
vine serum albumin (BSA) in Tris-buffered saline (TBS). Next, the dead or-
ganisms were incubated with the primary antibody 11B7 (1:500 dilution),
washed with PBS, incubated with a goat anti-mouse IgG secondary antibody
(1:2,500; Jackson Immunoresearch), andwashedwith PBS again before add-
ing the p-nitrophenyl phosphate substrate. Binding of antibody to capsular
material was quantitated by correlation to the production of the p-nitrophe-
nol product, whichwasmeasured by theOD405.Datawere normalized to the
value for the wild type (WT), which was arbitrarily set to 100%, and the
OD405/600 ratio of eachwellwas compared to that of the parent strain positive
control. An arbitrary cutoff of 15% of the WT level was used to identify F.
tularensis Schu S4 strains with reduced binding to the anti-capsule anti-
body. Additionally, mutants that met the 15% cutoff were characterized
further by a second enzyme-linked immunosorbent assay (ELISA) using
themonoclonal antibody FB11 (QEDBiosciences) to determine if the LPS
structure was also altered.
Identification of F. tularensis capsule mutants. Mutants of interest
were picked, plated ontoMMHagar containing kanamycin, and grown at
37°C with 5%CO2 for 48 h. A small loopful of bacteria was collected from
the agar plate to obtain genomicDNAby use of aDNeasy blood and tissue
kit (Qiagen). The genomic DNAwas digested with the restriction enzyme
EcoRI or NdeI, ligated with T4 DNA ligase, and then transformed into E.
coli pir-1 cells before plating on LB plates with kanamycin. This ap-
proach clones the majority of the transposon sequence, including the
kanamycin resistance gene and flanking DNA, since the Tn5lacZ trans-
poson carries the R6K plasmid origin of replication. Inclusion of this
plasmid origin on the transposon allows recovery of clones in E. coli host
strains that express the Pir protein for replication. Single colonies were
picked and grown in LB broth with kanamycin. Plasmid purification was
done by using a plasmidminiprep kit (Qiagen). A Tn5 primer was used to
sequence the genomicDNAflanking the transposon insertion at TheUni-
versity of Iowa School of Medicine DNA Core.
Protein similarity analysis and functional complementation exper-
iments.The F. tularensis Schu S4 FTT1236, FTT1237, and FTT1238c gene
products were compared to proteins encoded in the E. coli MG1655 ge-
nome by using NCBI’s position-specific iterated BLAST (PSI-BLAST)
function. HMMTOP andTMRPres2D software was used to predict trans-
membrane helices and topology of the FTT1238c gene product. Clustal
Omega was used to align sequences of WaaL proteins from E. coli and
Salmonella with the translated FTT1238c sequence of F. tularensis. Plas-
mids carrying sequences for FTT1236 (pSL129), FTT1237 (pSL130), or
FTT1238c (pSL149) were transformed into E. coli waa mutants (Keio
strains) or into the S. enterica SL1344 waaLmutant constructed for this
work and were selected on 50 g spectinomycin in L agar. Colonies were
picked and grown in L broth for 12 to 24 h at 37°C. Onemilliliter of broth
culture was centrifuged at 8,000  g for 2 min, the cell pellet was resus-
pended in buffer A, and organisms were lysed by heating at 65°C. Samples
were treated with proteinase K (Sigma) at 37°C for 24 h. Samples were
examined for carbohydrate content by a silver staining method. Briefly,
samples separated by SDS-PAGE were incubated in a mixture of 30%
Rasmussen et al.
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ethanol and 10% acetic acid for 30min. The solution was decanted before
incubation of the gel in 10% ethanol for 15 min. The ethanol was re-
moved, and 5% glutaraldehyde was added for 15min. The gel was washed
six times with double-distilled water (ddH2O) for 5 min each, and then
the gel was bathed in a 5-g/ml dithiothreitol (DTT) solution for 15 min.
AgNO3 (0.1%) was added, and the gel was incubated for 15 min. The gel
was thenwashed extensively with ddH2O and developedwith 3%Na2CO3
and 0.02% formaldehyde until bands appeared. A 3% acetic acid solution
was used to stop the reaction.
PAGE, immunoblotting, and emerald green staining of bacterial
whole-cell lysates. Francisella strains from newly streaked agar plates were
inoculated intoMMHbroth and grown for 24 h before the OD600 was mea-
suredand recorded.One-milliliter broth cultureswere centrifugedat 8,000
g for 2min before resuspension of each pellet in buffer A (6mMTris, 10mM
EDTA, and 2% [wt/vol] sodium dodecyl sulfate [pH 6.8]) and heating to
65°C to sterilize cultures. Bacterial lysates were then incubated with or with-
outproteinaseK(NewEnglandBioLabs, Ipswich,MA)at37°Cfor24hbefore
being lyophilized. Approximately 14g of bacterial material from each sam-
plewasmixedwithNuPage (Life Technologies, Carlsbad,CA) sample reduc-
ing agent and buffer, boiled for 10 min, loaded into a 4 to 12% Bis-Tris
NuPage gel, and electrophoresed using NuPage morpholineethanesulfonic
acid (MES)-SDS running buffer (Life Technologies, Carlsbad, CA). For im-
munoblots, sampleswere transferred tonitrocellulose andprobedwith either
the primary antibody 11B7 (to detect capsule) or FB11 (to detect LPS O
antigen) (QEDBioscience, SanDiego, CA). Bandswere visualized using goat
anti-mouse IgG(HL) conjugated to horseradish peroxidase (Jackson Im-
munoResearch,West Grove, PA) and SuperSignalWest Pico chemilumines-
cence substrate (Pierce Biotechnology, Rockford, IL). ProQ-Emerald 300
stain was used to visualize carbohydrates according to the instructions of the
manufacturer (Invitrogen).
LPS isolation. LPS was isolated by the method of McLendon et al.
(27). In brief, bacteria were grown for 16 h on chocolate agar with
appropriate antibiotics at 37°C, collected in 6 mM Tris base, 10 mM
EDTA, and 2.0% SDS (wt/vol), pH 6.8, containing 50g/ml proteinase K,
and incubated at 65°C for 1 h and then overnight at 37°C. To remove SDS,
samples were precipitated with 0.3 M sodium acetate and 3 volumes of
cold 100% ethanol, flash cooled in a dry ice-ethanol bath, and incubated
overnight at20°C. Samples were centrifuged for 10min at 12,000 g at
4°C, and pellets were suspended in deionized water and precipitated a
total of three times. Samples were suspended in water and treated with 80
U of micrococcal nuclease (Sigma, St. Louis, MO) for 2 h at 37°C. LPS
samples and phenol were equilibrated to 65°C, and an equal volume of
phenol was added to the lysates. Samples were mixed, incubated at 65°C
for 30 min, cooled, and centrifuged at 3,000 rpm for 10 min at 4°C. The
aqueous layer was collected, and the organic layer was back extracted with
an equal volume of water. The final aqueous samples were precipitated
with ethanol three times, and after the last precipitation, pellets were
suspended in high-pressure liquid chromatography (HPLC)-grade water
and lyophilized overnight.
Composition and linkage analyses of LPS. Composition analysis of
LPS samples was done by gas chromatography-mass spectrometry (GC-
MS) analysis of trimethylsilyl (TMS) derivatives of methylglycosides as
previously described (23). Briefly, LPS samples (100 g) containing 5 g
of myo-inositol as an internal standard were methanolyzed using 1 M
methanolic HCl at 80°C for 16 h, re-N-acetylated using CH3OH-pyri-
dine-acetic anhydride (4:1:1 [vol/vol/vol]) at 100°C for 1 h, dried, and
then silylated using Tri-Sil reagent at 80°C for 30 min. After removal of
Tri-Sil, samples were extracted in hexane and analyzed by GC-MS using
an Agilent GC-MS (Agilent Technologies 7820A GC attached to a 5975
series MSD) operating in the electron impact (EI) mode and equipped
with an Rtx-5ms column (30 m 0.25 mm 0.25 m; Restek). A tem-
perature gradient of 80°C to 140°C at 10°C/min, 140°C to 220°C at 2°C/
min (with a 1-min hold), and 220°C to 240°C at 5°C/min was used to
separate silylatedmonosaccharides.Monosaccharides were identified and
characterized by comparison to the retention times and fragmentation
patterns of authentic standards.
Linkage analysis of the LPS samples was performed using GC-MS
analysis of their partially methylated alditol acetate (PMAA) forms as
previously reported, with some minor modifications (23). Briefly, 0.4 mg
of each LPS sample was permethylated using amethodmodified from the
work of Ciucanu (28) and hydrolyzed to partially O-methylated mono-
saccharides, followed by reduction and peracetylation with sodium boro-
deuteride and pyridine-acetic anhydride, respectively. After dissolving in
dichloromethane, 1 l of the final PMAA sample was injected in splitless
mode and analyzed using the same GC-MS system and temperature gra-
dient, with the exception that the final temperaturewas 230°C. ThePMAA
peaks on the GC-MS chromatograph were identified by comparison with
some authentic standards and fragmentation patterns.
MALDI-MS analyses of LPS. To generate LPS that was more amena-
ble to mass spectrometric analyses, O-deacylated (O-LPS) samples were
prepared by treating100 g of LPS with 50 l of anhydrous hydrazine
followed by acetone precipitation as described previously (29). Addition-
ally, to remove contaminating free lipid A, some LPS samples were ex-
tractedwith chloroform-methanol-water (10:5:6 [vol/vol/vol]). The chlo-
roform phase was removed, and the aqueous phase and interface were
dried down under a stream of dry nitrogen; these samples were then O-
deacylated as described above. All samples were desalted by drop dialysis
using 0.025-m-pore-size nitrocellulosemembranes (Millipore, Bedford,
MA) and then lyophilized. Samples were reconstituted in 5 to 100 l of
HPLC-grade H2O; 1 l was loaded onto the target, dried, and then over-
laidwith 1l ofmatrix, consisting of 50mg/ml 2,5-dihydroxybenzoic acid
in 70% acetonitrile. Samples were subsequently analyzed using matrix-
assisted laser desorption ionization mass spectrometry (MALDI-MS) on
an LTQ linear-ion-trap mass spectrometer coupled to a vMALDI ion
source (MALDI-LIT; Thermo Fisher, Waltham, MA) operating with a
nitrogen laser at 337 nm, a 3-ns pulse duration, and a 60-Hz repetition
rate. Data were collected in the negative-ion mode, using the automated
gain control and the automatic spectrum filter settings. Tandem mass
spectrometry (MSn) data were collected using a precursor ion selection
window ofm/z 3 and a normalized collision energy of 35%.
Murine infections and organ dissemination. BALB/c female mice of
6 to 8 weeks of age were purchased from the National Cancer Institute
(NCI) for all sets of animal experiments. Groups of fivemicewere used for
evaluation of virulence of Francisella strains or immunization studies of
attenuated Francisella strains, and groups of three mice were used for
experiments in which bacterial growth in murine organs was examined.
Mice were infected intraperitoneally (i.p.) with 100-l inocula or intra-
nasally with 50-l inocula and were monitored for up to 26 days postin-
fection. Doses, ranging from 102 to 108 CFU, were estimated from OD600
readings and confirmed by dilution and plating of the bacterial suspen-
sion. For determination of bacterial burdens in organs,micewere infected
intranasally with 290 CFU, 2.2 106 CFU, or 2.4 106 CFU of F. tular-
ensis Schu S4, F. tularensis Schu S4 waaY (FTT1236), or F. tularensis Schu
S4 waaL (FTT1238c), respectively. Lungs, livers, and spleens were har-
vested on days 3, 6, 9, and 12. Data from Schu S4-infected mice were
collected only until day 5 postinfection, since all mice infected with Schu
S4 succumbed to infection after day 5. Organs were homogenized using
35-ml tissue grinders (Thermo Fisher Scientific) and 2 ml of 1% saponin
(Acros). Organ homogenates were serially diluted in PBS and plated to
enumerate the bacterial load per organ. The amount of growth for a strain
in the lung was determined by taking the amount of bacterial growth on
day 3, 6, 9, or 12 and dividing it by the initial inoculum. No statistical
significance was found for these data by use of the paired two-tailed Stu-
dent t test. All work with F. tularensis Schu S4 was performed within the
Carver College of Medicine Biosafety Level 3 (BSL3) Core Facility, and all
experimental protocols were reviewed for safety by the BSL3 Oversight
Committee of theUniversity of IowaCarver College ofMedicine. Recom-
binant DNA work with F. tularensis Schu S4 was approved by the Institu-
tional Biosafety Committee.
F. tularensis Mutants Attenuated for Mice
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Pathology ofmurine spleen, liver, and lungs.FourBALB/cmicewere
infected with 20 CFU of F. tularensis Schu S4, and groups of eight mice
were infected with 1.5  106 CFU of the F. tularensis Schu S4 waaY
(FTT1236) mutant or the F. tularensis Schu S4 waaL (FTT1238c) mutant.
Twomice from each group were sacrificed by CO2 inhalation, and organs
(lungs, liver, and spleen) were harvested on days 3, 6 (day 5 for WT-
infected mice), 9, and 12. Tissues were fixed in 10% formalin in nonbuf-
fered saline. Fixed tissues (lungs, liver, and spleen) were submitted to the
Comparative Pathology Laboratory (University of Iowa) for routine tis-
sue processing, paraffin embedding, sectioning (4 m), and hematox-
ylin and eosin (HE) staining. Tissue sections were examined, and digital
images were collected using a high-resolution digital camera (DP71;
Olympus) on a BX51 microscope (Olympus). Scoring of lung tissues was
performed following the principles of histopathologic scoring (30).
Groups of 5 BALB/c mice were infected with 33 CFU of Francisella tular-
ensis Schu S4, 1.4 106 CFU of F. tularensis waaY::TrgTn, 1.4 106 CFU
of F. tularensis waaL::TrgTn, 27 CFU of F. tularensis waaY::TrgTn/
pSL129, or 45 CFU of F. tularensis waaL::TrgTn/pSL149. Organs were
harvested and fixed as described above on day 4 postinfection. Scoring
parameters for necrotic debris in airspaces were as follows: 0, no necrosis
detected; 1,	25% of airspaces obstructed with necrotic cellular debris; 2,
25 to 50% of airspaces obstructed with necrotic cellular debris; 3, 51 to
75% of airspaces obstructed with necrotic cellular debris; and 4,
75% of
airspaces obstructed with necrotic cellular debris. Statistical significance
of semiquantitative scoring was determined using Prism v5 software,
Kruskal-Wallis one-way analysis of variance (ANOVA), and the Dunn
posttest. Significance was set at 0.05.
Immunization with capsule/O-antigen F. tularensis mutants.
Groups of five BALB/c mice were infected with 76 CFU of F. tularensis
Schu S4 i.p. in 100 l of PBS. Groups of five mice were infected i.p. with
three different doses of the F. tularensis waaY (FTT1236) and waaL
(FTT1238c)mutants.Mice infectedwith the F. tularensis waaY (FTT1236)
mutant were given doses of 5.6 102, 5.6 103, and 5.6 104 CFU,while
mice infected with the F. tularensis waaL (FTT1238c) mutant were given
doses of 9.6 102, 9.6 103, and 9.6 104CFU.At 14 days postinfection,
mice were boosted i.p. with 5  105 CFU of the same strain that was
originally used to challenge themice. After an additional 28 days, themice
infected with the F. tularensis Schu S4waaY (FTT1236)mutant were chal-
lenged i.p. with 20, 200, and 2,000 CFU of Schu S4, and the F. tularensis
Schu S4 waaL (FTT1238c) mutant-infected mice were challenged intra-
nasally with 20, 200, and 2,000 CFUof Schu S4. A group of sevenmice was
infected i.p. with F. tularensis Schu S4 as a positive control. Each group of
mice was monitored for 14 days after challenge with the F. tularensis Schu
S4 parent strain.
To examine the efficacy of vaccinatingmice by the intranasal route (5),
groups of five BALB/c mice were immunized intranasally with the sub-
lethal dose of 675 CFU of the F. tularensis waaY::TrgTn mutant. Two of
the groups of mice were boosted with 500 CFU intranasally at day 14,
while the other three groups of mice were left unboosted. At 28 days
postvaccination, the mice were challenged with various doses of F. tular-
ensis Schu S4 to determine the level of protection provided by the F.
tularensis waaY::TrgTn mutant.
RESULTS
Screening for capsule-deficientmutants in an F. tularensis Schu
S4 Tn5 library. To identify F. tularensis Schu S4 mutants lacking
capsule production, we screened an F. tularensis Schu S4 Tn5
transposon insertion library, comprising7,500 F. tularensismu-
tants (4-fold coverage of the Schu S4 genome), with the 11B7
monoclonal antibody to capsule (23). A total of 116 isolates with
significantly reduced binding (	15% of the wild-type level) were
initially identified as candidate capsule mutants for further char-
acterization. Confirmatory screening (screening the 116 isolates
again with 11B7) of these strains revealed that only 10 of these
strains reproducibly had less than 15% of wild-type binding to the
11B7 antibody, and these were selected for further characteriza-
tion. To identify disrupted genes, transposon elements (i.e., the
kanamycin resistance gene and the R6K origin of plasmid replica-
tion) and flanking chromosomal DNA were rescued from these
strains by restriction enzyme digestion and ligation to create plas-
mids that replicated within E. coli pir strains. The plasmids were
sequenced across the transposon insertion site to determinewhich
gene the transposon had disrupted. Sequence analysis revealed that
these 10 strains represented insertions in seven different Francisella
genes (Table 1), with three separate mutations in one gene
(FTT1238c) and two identical insertions in another gene
(FTT1236). In addition to finding capsule defects in each of these
F. tularensis Schu S4 mutants, we also found LPS defects in these
mutants. In previously published work, our laboratory identified
the FTT1236, FTT1237, and FTT1238c genes as being important
for intracellular growth in human monocyte-derived macro-
phages (MDMs) by screening of an F. tularensis Schu S4 TraSH
library for genes required for intracellular survival (25). To con-
firm thatmutations in these genes did significantly reduce capsule
and LPS antibody binding, we examined our previously con-
structed mutants in FTT1236, FTT1237, and FTT1238c by ELISA
for capsule production and found that theFTT1236 andFTT1238c
mutants each had 	15% reactivity, while the FTT1237 mutant
had 74% reactivity to the anti-capsule 11B7monoclonal antibody
compared to the WT strain. In the ELISA, the F. tularensis
FTT1236 mutant had 39% reactivity, the F. tularensis FTT1237
mutant had 50% reactivity, and the F. tularensis FTT1238cmutant
had 33% reactivity to the anti-LPS FB11 monoclonal antibody
compared to the reactivity for the F. tularensis Schu S4 parent
strain (100% reactivity). These results are consistent withWestern
blot data showing that mutations in these genes abolish capsule
production and significantly reduce LPS O-antigen laddering
(25).
Geneproducts ofFTT1236,FTT1237, andFTT1238c are sim-
ilar to E. coli Waa proteins and functionally complement waa
mutants in E. coli or Salmonella. The proteins produced by
FTT1236, FTT1237, and FTT1238c are annotated as hypothetical
proteins in Francisella genome sequences. In an effort to under-
stand how mutation of these genes alters biosynthesis of capsule
and LPS, we analyzed the predicted translational product of each
gene. Using NCBI protein PSI-BLAST to search for homology, we
discovered that these genes share some similarity with the Waa
protein genes of Escherichia coliMG1655 (Fig. 1A). The FTT1236






Predicted function of gene
product
FTT0025c (fslE) 137 Iron acquisition protein
FTT0846 896 Potential deoxyribodipyrimidine
photolyase
FTT1138 (hemH) 637 Potential ferrochelatase
FTT1236 688 Hypothetical protein
FTT1238c 463, 681, 989 Hypothetical protein
FTT1458c (wzy) 593 O-antigen polymerase
FTT1464c (wbtA) 641 dTDP-glucose 4,6-dehydratase
a Identified by reduced binding of the gene mutants to anti-capsule antibody; all
mutants had binding that was less than 15% of the WT level.
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gene product has regions of similarity (24% similarity) to E. coli
WaaB (Fig. 1A). Analysis of FTT1237 revealed significant regions
of similarity to the E. coliWaaI andWaaJ proteins (41% and 43%
similarities, respectively). FTT1238c was compared to E. coli
WaaL and S. enterica WaaL, and regions of similarity were ob-
served for both (43% and 40% similarities, respectively).With the
aid of Clustal Omega (31), the F. tularensis FTT1237 protein se-
quence was compared to the E. coli WaaI and WaaJ sequences,
revealing a DxD motif, which is a characteristic of glycosyltrans-
ferases (Fig. 1B). Additionally, the F. tularensis FTT1238c protein
sequence was compared to the E. coliWaaL and SalmonellaWaaL
sequences, revealing a conserved histidine residue and a conserved
arginine residue that have been shown to be important for func-
tion in other organisms (32–34) (Fig. 1B). In E. coli as well as other
Gram-negative organisms, Waa proteins are important for LPS
core biosynthesis (i.e., core sugar assembly) and for ligation of the
FIG 1 Similarity of F. tularensisWaa proteins to E. coli and S. enterica proteins. (A) Francisella proteins FTT1236, FTT1237, and FTT1238c are similar to E. coli
(*) and S. enterica (‡) LPS biosynthetic proteins. (B) In the protein alignments, single dots denote semiconserved residues, double dots are conserved residues,
and asterisks identify exact matches of amino acid residues. Individual alignments are separated by thick black lines. The FTT1237 protein has a DxD motif
(shown in bold) that is conserved in both WaaI and WaaJ of E. coli. Alignment of the FTT1238c protein to the E. coli and S. entericaWaaL proteins reveals the
presence of the highly conserved arginine and histidine amino acids (in bold) that are important for the function of the protein. (C) Themembrane topologymap
of FTT1238c shows the 12 predicted transmembrane domains as well as a large periplasmic loop containing the conserved arginine (*; R270) and histidine (**;
H361) residues.
F. tularensis Mutants Attenuated for Mice
April 2014 Volume 82 Number 4 iai.asm.org 1527
 o
n
 April 20, 2014 by W







O-antigen repeating unit to the synthesized core (24). Using the
programs HMMTOP (35, 36) and TMRPres2D (37) to predict
membrane topology, we constructed a transmembrane model for
the FTT1238c gene product (Fig. 1C). As for otherWaaL proteins,
the FTT1238c gene product was predicted to have 12 transmem-
brane segments, 5 cytoplasmic loops, 6 periplasmic loops, and
localization of both the N and C termini in the bacterial cyto-
plasm. The large periplasmic loop between segments 9 and 10
contains the highly conserved residues R270 and H361.
To explore possible functions for the Francisella FTT1236,
FTT1237, and FTT1238c genes, we obtained E. colimutants in the
waaB,waaI, andwaaJ genes from the Keio collection to determine
whether Francisella genes could functionally complement the LPS
biosynthetic defect in these E. colimutants. Since the E. coli parent
strain (BW25113) also lacks the ability to synthesize O antigen, we
could not use this strain to attempt to complement a waaL defect.
Accordingly, we constructed a waaL mutant in S. enterica Typhi-
murium SL1344 to assay for functional complementation with a
plasmid carrying the intact FTT1238c gene (pSL149).When the F.
tularensis FTT1236 gene (pSL129) was introduced into the E. coli
waaBmutant, the core sugar bands were observed to have a slight
yet detectable shift in comparison to the uncomplementedmutant
strain (Fig. 2A). When a plasmid with F. tularensis FTT1237
(pSL130) was introduced into the E. coli waaI or waaJ mutant,
there was a slight yet detectable shifting of the carbohydrate bands
in comparison to the uncomplemented mutant strain (Fig. 2A).
We therefore observed partial complementation of E. coli LPS
biosynthetic defects with both the Francisella FTT1236 and
FTT1237 genes. As negative controls for functional complemen-
tation, E. colimutants in waaG and waaQ did not show any com-
plementationwhen complementedwith either pSL129 or pSL130.
Introduction of a plasmid with a functional copy of the FTT1238c
gene (pSL149) into the Salmonella waaL mutant partially re-
stored the O-antigen banding that was observed in the parent
SL1344 strain (Fig. 2B). We observed no shift in carbohydrate
bandmigration for strains carrying empty vectors as negative con-
trols (data not shown). The presence of any complementation in
these experiments is considered significant due to the species-
specific requirements for these LPS biosynthetic enzymes. We be-
lieve that this is particularly true for Francisella, since the LPS of
this organism is very different from those of the Enterobacteriaceae
(13, 14) and the similarities that we have detected between the
Francisella genes and E. coli/Salmonella genes are quite low.
F. tularensis waa mutants have altered LPS core structures.
Previously, we showed that the FTT1236::TrgTn, FTT1237::TrgTn,
and FTT1238c::TrgTn mutants were sensitive to complement (25),
consistent with observations that waa mutants of other organisms
also display significantly increased sensitivity (38–40). To examine
other phenotypes of our mutants, we prepared whole-cell lysates of
the FTT1236::TrgTn, FTT1237::TrgTn, and FTT1238c::TrgTn mu-
tants to determine if core sugars were altered. Whole-cell lysates of
each strain were separated by SDS-PAGE, and the samples were
stained for carbohydrates (Fig. 3A). We observed that the FTT1236
mutant and theFTT1237mutant eachhadcore sugardefects and that
the FTT1236 mutant strain was more truncated in its core than the
FTT1237 mutant. These types of core sugar shifts were consistent
with core sugar changes previously observed in E. coli waa mutants
(40, 41). In contrast, the waaLmutant appeared to have a complete
lipid A and core sugar structure but lacked O-antigen laddering as
previously described (40). This result provides additional evidence
that the FTT1238c gene product is similar toWaaL, as other bacterial
strains mutated at waaL cannot ligate the O antigen to the LPS core
and therefore also do not have O-antigen laddering.
Since previous work indicated that the FTT1237::TrgTn strain
has a less attenuated phenotype than either the FTT1236 or
FTT1238cmutant, we focused our remaining work on the pheno-
types of the latter two mutants. LPS species from the Schu S4
FTT1236 and FTT1238c mutants were isolated and subsequently
O-deacylated to make the LPS more amenable to mass spectro-
metric analyses. MALDI-MS analyses of these samples showed
abundant peaks corresponding to O-deacylated lipid A, with no
additional carbohydrate component detected (data not shown).
Multiple samples were tested using our standard protocols, and
each time only O-deacylated lipid A was detected at m/z 983 and
1,144.
Sincewewere unable to successfully detectO-LPS components
from the Schu S4 strains, we created mutations in the analogous
LVS genes and used LPS isolated from the LVSmutant strains.We
have shown previously that the lipid A-core sugar bands from
these strains appear identical to those from the Schu S4 mutants
(data not shown). The analogous LVS strain for the Schu S4 1236::
TrgTn mutant is LVS 0708::TrgTn, and the corresponding LVS
strain for the Schu S4 1238c::TrgTn mutant is LVS 0706::TrgTn.
The use of these F. tularensis LVSmutants allowed us to use larger
starter culture volumes to generate larger quantities of LPS for
analyses, which were isolated as previously detailed. As described
above, the LPS samples wereO-deacylated and subsequently ana-
lyzed by MALDI-MS. Initial analyses of these O-deacylated LPS
preparations clearly demonstrated that we were able to detect O-
LPS components in the LVS 0708::TrgTn strain, but the most
abundant peak detected was that corresponding to the O-deacy-
lated lipid A (data not shown). To decrease the amount of free
FIG 2 Functional complementation of E. coli and S. enterica mutants in waa
genes with Francisella tularensis genes. (A) E. colimutants in waaB, waaI, and
waaJ from the Keio collection were complemented with a plasmid carrying
either FTT1236 (pSL129) or FTT1237 (pSL30). Proteinase K-treated whole-
cell lysates were prepared for each strain, separated by PAGE, and visualized by
silver staining. *, upwardmobility shift of lipid A-coremolecules in each E. coli
strain. (B)Whole-cell lysates (proteinaseK treated) of S. enterica SL1344, the S.
enterica waaL mutant, and the S. enterica waaL mutant complemented with
FTT1238c (pSL149) were separated by PAGE, and O-acylated species were
visualized by silver staining.
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lipid A present in the LPS samples, intact LPS was extracted with
chloroform-methanol-water, and the aqueous and interface layers
were isolated, O-deacylated, and subsequently analyzed by
MALDI-MS. Indeed, the most intense peak was then observed at
m/z 1,747.55, with less abundant peaks at m/z 1,649.45, 1,585.55,
1,527.55, 1,365.55, and 983.55. The mass observed at m/z 983.55
corresponds to O-deacylated lipid A containing one phosphate
group and agrees with the previously predicted lipid A structure
(13, 14).
To determine the individual components of the O-LPS struc-
ture, multistage mass spectrometric analyses (MSn) were per-
formed (Fig. 3B). MS/MS analyses of the major peak at m/z
1,747.55 showed the generation of twomajor peaks, atm/z 1,527.5
and 983.58 (Fig. 3C). The mass difference between the precursor
ion, m/z 1,747, and the fragment ion at m/z 1,527 is 220 Da, cor-
responding to the loss of one 2-keto-3-deoxyoctulosonic acid
(KDO) moiety. Further fragmentation (MS3) of the peak at m/z
1,527 generated one major peak, at m/z 983.58, which is O-deac-
ylated lipid A (Fig. 3D). The mass difference between the precur-
sor ion peak at m/z 1,527.5 and the ion at m/z 983.58 is 544 Da,
which could nominally be attributed to two hexoses and one
KDO.Composition analyses of LVS 0708::TrgTn showed the pres-
ence of mannose (Man), glucose (Glc), and KDO, suggesting that
the 544 Da consisted of one KDO, Glc, and Man. MS analyses
demonstrated that the loss of one KDO or one hexose could read-
ily be observed as one of the first losses from theO-LPS, confirm-
ing that both of these sugars are at terminal positions. Linkage
analysis confirmed the presence of both Glc and Man as terminal
sugars in the LVS 0708::TrgTn LPS structure (Fig. 3E). Additional
peaks were observed in the spectrum, including peaks that corre-
sponded to components of the lipid A and to probable KDO deg-
radation products and some peaks which could not be attributed
to the known LPS structure. The previously published wild-type
LVS LPS structure identified only one KDO moiety in the core
structure (14); however, our data clearly demonstrate the presence
of a second KDO moiety as part of the core structure, which is
most likely linked to the other core KDO moiety.
MALDI-MS analyses were also performed on the O-LPS from
the LVSwaaLmutant LVS706. InitialMSdata from the LVS 0706::
TrgTn O-LPS once again showed only the presence of O-deacy-
lated lipid A; therefore, a chloroform-methanol-water extraction
was performed on the intact LVS 0706::TrgTn LPS to reduce the
FIG 3 Examination of the lipopolysaccharide core structures of O-antigen mutants by staining of carbohydrates and negative-ion multistage MALDI-MS. (A)
Consistent with previously published data (58–60), the bands in the purified LPS lane shown in the PAGE gel and stained by emerald green are labeled lipid
A–core–O-antigen (one unit), lipid A-core (no O-antigen subunit), and lipid A and are indicated by black arrows. (B) MALDI-MS analysis of O-LPS derived
from the LVS 0708 mutant. MSn analyses were performed to sequentially determine the components of the O-LPS. (C) MS/MS analysis of the precursor ion
observed atm/z 1,747. (D) Subsequent MS3 analysis performed on the fragment ion observed atm/z 1,527. Peaks marked with asterisks designate major masses
minus water or CO2. (E) Completed core structure for LVS 0708::TrgTn (predicted for the Schu S4 1236::TrgTn strain as well) and predicted structure for LVS
0706::TrgTn (as well as the Schu S4 1238::TrgTn strain).
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free lipid A components in this preparation. As expected, the in-
tensity of the O-deacylated lipid A peak decreased dramatically
after this extraction; however, a higher-mass substituted O-LPS
was not detected. To gain further insight into the LVS 0706::TrgTn
LPS structure, composition analyses were performed. These data
showed the presence of Man, Glc, KDO, GalNAc, and GlcNAc in
the LVS 0706::TrgTn strain. The GlcNAcwas seen in both the LVS
0706::TrgTn and LVS 0708::TrgTn LPS samples and was likely
derived from lipid A. The remaining constituents are components
of the LPS core. Comparisons of the composition analyses of the
LVS 0706::TrgTn and LVS 0708::TrgTn LPS species showed that
the LVS 0706::TrgTn LPS contained higher levels of Man and Glc
and contained one GalNAc, whereas GalNAc was not detected in
the LVS 0708::TrgTn LPS sample. Linkage analyses confirmed the
presence of terminal Glc and GalNAc as well as 2,3-Man and 2,4-
Man, correlatingwith the previously published LPS structure. Ad-
ditional peaks were observed which corresponded to the GlcNAc
from lipid A and to probable KDO degradation products, with
some peaks which did not correlate with the published LPS struc-
ture. These data combinedwith the previously published LVS core
structure indicate that the LVS 0706::TrgTn LPS consists of a full
core structure like that of the wild type (14, 42), including an
additional KDOmoiety linked to the other coreKDOresidue (Fig.
3E). Due to these results, we refer to the FTT1236 gene as waaY,
the FTT1237 gene as waaZ, and the FTT1238c gene as waaL.
Determination of virulence and organ dissemination inmu-
rine infections. We previously demonstrated that when human
MDMs were infected with either the waaY or waaL mutant, the
organisms gained entry into the cells in larger numbers and caused
cell death of MDMs 30 h sooner than the WT strain (25). We
wanted to extend these observations by examining the virulence of
these strains in a murine model of disease. We infected mice with
F. tularensis Schu S4 (12 CFU), the waaY mutant, or the waaL
mutant at doses ranging from 102 to 108 CFU via the intraperito-
neal (i.p.) or intranasal (i.n.) route of infection. The i.p. infection
experiments revealed that the F. tularensis mutants were signifi-
cantly attenuated for mouse virulence when inoculated into the
peritoneal cavity. The accepted 50% lethal dose (LD50) of F. tula-
rensis Schu S4 for BALB/cmice is	10CFU, and the group ofmice
infected with 12 CFU of Schu S4 all died within 5 days. However,
the i.p. LD50 for the F. tularensis waaYmutant was calculated (43)
to be 7.6  106 CFU, and the i.p. LD50 for the F. tularensis waaL
mutant was calculated to be 3.8 105 CFU, which are about 105
and 104 reductions in virulence, respectively, for these strains.
This result was not completely surprising, since we have previ-
ously reported that these strains are highly sensitive to comple-
ment killing (25).
For mice that were challenged intranasally, we used 10-fold
dilution doses from 103 to 108 CFU and observed the animals
for signs of disease for up to 26 days postinfection (Table 2). Re-
gardless of the infectious dose, mice that were infected with each
of themutants appeared sick, as the fur was ruffled for 2 days after
the infection. Minimal conjunctivitis was observed on days 4
through 6 postinfection. Typically, a day or two before becoming
moribund (for all doses), themice intranasally infected with these
mutant strains had moderately severe conjunctivitis and began to
have labored breathing which worsened significantly until the
mice succumbed. Using the calculation method of Reed and
Muench (43), we determined that the LD50 for i.n. infection of
mice with the waaY mutant was 1.3  104 CFU, and that for the
waaL mutant was 3  103 CFU. To determine the bacterial bur-
dens in organs, we intranasally infected groups of BALB/c mice
with300 CFU of Schu S4 and 2 106 CFU of thewaaY orwaaL
mutant strain. At these doses, wild-type-infected mice died at
about day 5, and F. tularensismutant-infected mice died at about
day 13. On days 3, 6, 9, and 12 postinfection, we harvested the
lungs, liver, and spleen and plated dilutions of the organ homog-
enates to determine the bacterial burden carried in each organ.
Organ burdens inWT-infectedmice were evaluated only on day 3
postinfection, as all mice had succumbed to the infection by day 6
(Fig. 4A). Regardless of when organ burdens were examined,mice
infected with the mutant strains did not clear the infections from
the lungs, liver, or spleen. During early stages of infection, these
strains persisted at low levels in the liver and spleen, although by
day 12 the levels of growth were comparable to those observed for
the virulentWT Schu S4 strain at day 3 postinfection. In contrast,
the lungs of mice infected with either the waaY or waaL mutant
had significantly higher levels of bacterial growth than the WT
strain (106 CFU/organ) at 3 days postinfection, with the burden in
the lungs continuing to increase exponentially, to 1011 CFU/organ
by day 12 postinfection. In comparing the growth on day 3 postin-
fection, the trend points to the mutants having slower growth
kinetics in vivo than that of theWT (Fig. 4B). By day 12 postinfec-
tion, the mutants had relatively similar growth to that of the WT
on day 3 postinfection. These data suggest that the organ lung
burdens were similar for the mutants and the WT prior to mouse
death (WT-infected mice died on day 5 or 6 postinfection,
whereas mutant-infected mice, at the dose given, died on days 13
TABLE 2 Murine virulence studies of F. tularensis Schu S4, F. tularensis











Schu S4 12 0/5 5
waaY::TrgTn 1.8 104 5/5 
14
1.8 105 5/5 
14
1.8 106 5/5 
14
2.2 107 1/5 3.75,
14
2.2 108 0/5 3.2
waaL::TrgTn 1.2 104 5/5 
14
1.2 105 5/5 
14
1.2 106 0/5 5
2.4 107 1/5 3.75,
14
2.4 108 0/5 2.8
i.n. infection
Schu S4 16 0/5 6
waaY::TrgTn 1.3 103 5/5 
26
1.3 104 2/5 19.3,
26
1.3 105 1/4 16.6,
26
1.3 106 0/5 18
1.3 107 0/5 19.8
1.3 108 0/5 15.8
waaL::TrgTn 7 102 5/5 
26
2.4 104 0/5 16.2
7 104 1/5 19,
26
7 105 0/5 12
7 106 1/5 15,
26
7 107 0/5 11.6
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FIG 4 F. tularensis O-antigen mutants in the waaY or waaL gene are able to disseminate to and replicate in the mouse liver and spleen. (A) BALB/c mice were
intranasally infected with 300 CFU of F. tularensis Schu S4, 2.2  106 CFU of F. tularensis waaY::TrgTn, or 2.4  106 CFU of F. tularensis waaL::TrgTn.
Homogenates of the lungs, liver, and spleen were plated from mice infected for 3, 6, 9, or 12 days to determine bacterial counts per organ. Horizontal lines
represent themeans of the organ counts for each strain at each time point. (B) From the initial inoculum to day 3 postinfection, fold growth of bacteria in the lung
was calculated for Schu S4 andmutants. Fold growth was also calculated formice infected with themutants after day 3 postinfection. Comparison of fold growth
after day 3 postinfection in mice infected with mutants could not be compared to that in Schu S4-infected mice because Schu S4-infected mice died before day
6 postinfection.
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to 15 postinfection). Another significant observation from these
murine infection studies is that highly serum-sensitive F. tularen-
sismutant strains are still able to colonize, grow within mice, and
cause fatality at relatively low doses when delivered intranasally.
This suggests that complement is low in abundance in the lungs or
that the organisms are able to escape its killing action by an un-
known and unanticipated mechanism.
Pathology of murine tissues infected with F. tularensis Schu
S4 or the waaY or waaLmutant. (i) Spleen. Three days after in-
tranasal inoculation, mice inoculated with WT bacteria lacked
lesions in the spleen (Fig. 5a), but by day 5 postinfection, the
splenic red pulp had become effaced by coalescing to diffuse case-
ous necrosis that extended into the periphery of the white pulp
(Fig. 5b). In contrast, on day 3 postinfection,mice inoculatedwith
either the waaY or waaL mutant had increased numbers of neu-
trophils in the red pulp (Fig. 5c). At day 6 postinfection, the red
pulp continued to have neutrophilia, with detectable small islands
of granulocytic/myeloid-predominant extramedullary hemato-
poiesis and rare thrombi (Fig. 5d and e). At day 12 postinfection,
mice inoculated with the mutant strains had a prominent lym-
phoid hyperplasia characterized by germinal centers in the splenic
white pulp, while the red pulp commonly had extramedullary
hematopoiesis with neutrophilia and an absence of thrombi or
necrosis (Fig. 5f).
(ii) Liver. At day 3 postinfection, both inoculation groups
had similar liver changes, characterized by sporadic focal neu-
trophil and macrophagic inflammation (pyogranulomas). At
day 5 postinfection, mice from the WT inoculation group had
multifocal hepatic parenchymal necrosis, with numerous Kupffer
cells distended by bacteria. From days 6 to 12 postinfection, livers
frommice infected with the F. tularensis waaY and waaLmutants
had multifocal pyogranulomas similar to those seen on day 3
postinfection, but they also had multifocal evidence of extramed-
ullary hematopoiesis, with rare necrosis, thrombi, and multifocal
extramedullary hematopoiesis that did not produce obvious tem-
poral group changes.
(iii) Lungs. By day 3 postinfection, mice inoculated with WT
bacteria lacked overt lung inflammation or lesions (Fig. 6a). By
day 5 postinfection, WT groups had multifocal caseous necrosis
that was often centered on vessel walls (Fig. 6b). At times, the
necrosis resulted in complete obliteration of the vessel and adja-
cent tissue. In contrast, at day 3 postinfection, mice inoculated
with mutant bacteria had multifocal airspaces in the lungs filled
with necrotic cellular debris and inflammation that was often lo-
cated in peribronchiolar/perivascular regions of small airways
(Fig. 6c). At day 6 postinfection and through the end of the time
course, thesemultifocal lesions continued to expand (Fig. 6d), and
by day 12 postinfection, they effaced themajority of lung airspaces
and airwayswith necrotic cellular debris, inflammatory cells (neu-
trophils and macrophages), and edema (Fig. 6e and f).
The lung lesions were semiquantitatively measured by scoring
the necrotic cellular debris (determining the percentage of pulmo-
FIG 5 Pathology of spleens infected with F. tularensis Schu S4, the F. tularensis waaYmutant, and the F. tularensis waaLmutant. Sections of spleens are shown
for mice infected with Schu S4 for 3 and 5 days (a and b) or with F. tularensismutant strains for 3, 6, and 12 days (c to f). The lesions observed in samples from
F. tularensis waaY and F. tularensis waaLmutant infectionswere indistinguishable fromone another. (a) Spleen section from F. tularensis Schu S4-infectedmouse
at 3 days postinfection. (b) Spleen section from F. tularensis Schu S4-infected mouse at 5 days postinfection. The white asterisks denote areas of diffuse to
coalescing necrosis in the red pulp. (c and d) Spleen sections from F. tularensismutant-infected mouse at 3 days postinfection (c) and 6 days postinfection (d).
The spleen had increased neutrophils (arrows) in the red pulp. (e) Spleen section from F. tularensismutant-infected mouse at 6 days postinfection. The spleen
had rare thrombi in red pulp (black asterisk) and lacked detectable necrosis. (f) Tissue section from F. tularensismutant-infectedmouse at 12 days postinfection.
The spleen had white pulp with large germinal centers (white asterisk) and red pulp with granulocytic/myeloid-predominant extramedullary hematopoiesis
(arrows). The scale bar applies to each panel shown.
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nary airspaces that were obstructed by necrotic debris). F. tular-
ensis Schu S4, waaY::TrgTn, and waaL::TrgTn and the comple-
mented mutant strains were scored for lung inflammation from 5
sets of murine lungs on day 4 postinfection. F. tularensis Schu
S4-infected mice were given a ranking of only 1, even though the
animals were moribund on day 5 (Fig. 7). For the mice infected
with the F. tularensismutants, the lung scores were similar for the
waaY::TrgTn and waaL::TrgTn mutants, and these were both sig-
nificantly increased compared to those for the wild type. Infec-
tions with the complemented mutant strains appeared like WT
infection and were not significantly different from WT infection.
It is interesting that when mice were infected with the comple-
mented mutants at20 to 40 CFU, they succumbed to infection,
albeit with slightly delayed timing relative to that for typical Schu
S4 infections at these doses (data not shown). Taken together,
these data provide additional support for the gross inflammation
that these F. tularensismutants elicit in the lungs of infected mice,
in contrast to the lack of inflammation within the lungs of wild-
type-infected mice, even at the point of death.
Immunization with F. tularensis mutants and subsequent
challenge with Schu S4. In previous studies, we immunized mice
with Francisella capsular material and demonstrated that this im-
munization elicited an antibody response against capsule. How-
ever, an ensuing challenge of the immunized mice with Schu S4
yielded no protection, although the mice were protected signifi-
FIG 6 Pathology of lungs infectedwith Schu S4 and thewaaY andwaaLmutants. Lung sections are shown formice infected for 3 and 5 days with F. tularensis Schu S4
(a and b) or for 3, 6, and 12 days with F. tularensismutant strains (c to f). The lesions observed in samples from F. tularensis waaY and F. tularensis waaLmutant
infections were indistinguishable from one another. (a) Lung section from F. tularensis Schu S4-infected mouse at 3 days postinfection. Lungs lacked overt
lesions. (b) Lung section from F. tularensis Schu S4-infectedmouse at 5 days postinfection. Multifocal vessels (large and small) had segmental to circumferential
necrosis of the vascular wall (arrows), without overt inflammation in airways or lumens (asterisk). (c and d) Lung sections from F. tularensis mutant-infected
mouse at 3 days postinfection (c) and 6 days postinfection (d). Lungs (day 3) had necrotic cellular debris and inflammation (neutrophils and lessermacrophages)
that localized near distal airways/vessels, with extension into the adjacent parenchyma (c; arrows). (d) Lungs had perivascular inflammation (arrow) with
progressive expansion of the lesions (necrotic debris, neutrophils, macrophages, and some edema) into adjacent parenchyma and airway lumens (asterisk). (e
and f) By day 12 postinfection, pathology in the lungs of mice infected with F. tularensis mutant strains had progressed to diffuse airspace consolidation, with
filling of most airways (e; asterisks) by edema, necropurulent debris (f; asterisks), and macrophages (f; arrows). The scale bar in panel a applies to panels a to e.
FIG 7 Comparison of necrotic debris for Schu S4, Francisella tularensis waaY
and waaL mutants, and complemented mutants. Groups of 5 BALB/c mice
were infected with 33 CFU of Francisella tularensis Schu S4, 1.4 106 CFU of
F. tularensis waaY::TrgTn, 1.4 106 CFUof F. tularensis waaL::TrgTn, 27CFU
of F. tularensis waaY::TrgTn plus pSL129, or 45 CFU of F. tularensis waaL::
TrgTn plus pSL149. On day 4 postinfection, lungs were scored for percent
airspace filled with necrotic debris. 0, no detected necropurulent debris in the
airspaces; 1, 0 to 25% of airspaces partially to fully obstructed by necrotic
cellular debris; 2, 25 to 50% obstructed; 3, 50 to 75% obstructed; 4, 
75%
obstructed. *, P	 0.01; **, P	 0.05; NS, not significant. P values were deter-
mined using Prism v5 software, Kruskal-Wallis one-way ANOVA, and the
Dunn posttest.
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cantly against challenge with F. tularensis LVS (23). With our cur-
rent study of O-antigen/capsule mutants, we explored the poten-
tial of using F. tularensis waaY and waaL mutant strains as a
vehicle to provide protection against a lethal Schu S4 challenge. A
preliminary vaccine experiment was performed using mice that
had been exposed to either F. tularensis waaY::TrgTn or F. tular-
ensis waaL::TrgTn in the virulence study. In this experiment, mice
that survived intraperitoneal challenge with 560, 5,600, or 56,000
CFU of the waaY::TrgTn mutant or 960, 9,600, or 96,000 CFU of
thewaaL::TrgTnmutant were challenged with 5 105 CFU of the
strain that was originally used to infect the mice. Twenty-eight
days later, the waaY mutant-infected mice were reinfected i.p.
with 20, 200, or 2,000 CFU of Schu S4 (Fig. 8A), while the waaL
mutant-infected mice were challenged i.n. with 20, 200, or 2,000
CFU of Schu S4 (Fig. 8B). Control mice were given a dose of 20
CFU i.p., and all succumbed to infection by 6 days postinfection.
Of the waaY mutant-immunized mice, 4 of 5 mice (80%), 3 of 5
mice (60%), and 1 of 5 mice (20%) survived the Schu S4 doses of
20, 200, and 2,000 CFU, respectively. Interestingly, 5 of 5 (100%)
of the waaL mutant-immunized mice that were challenged with
either 20 or 200CFUof Schu S4 i.n. survived, while 4 of 5 (80%) of
the waaLmutant-immunized mice survived challenge with 2,000
CFU of Schu S4 i.n. This preliminary experiment provides strong
evidence that mice challenged intraperitoneally with sublethal
doses of either of the two mutant strains can elicit a protective
immune response against challenge with up to 2,000 CFU of Schu
S4. It is worth noting that in our laboratory, every naive mouse
challenge experiment with wild-type F. tularensis Schu S4 has re-
sulted in death of the mouse, suggesting that a single organism
may always be lethal for mice. The protection that we observed in
these experiments is of high interest, even though the experimen-
tal protocol had many variables.
Since the previous infection experiment had differing challenge
doses,weperformedanother experimentwith theF. tularensiswaaY::
TrgTn strain. Five groups of five BALB/cmicewere challenged intra-
nasally with 675 CFU of thewaaY::TrgTn strain, which is a sublethal
dose. Two groups of five mice were boosted intranasally with 500
CFU of the waaY::TrgTn strain, while the other three groups of five
micewere not boosted. The unboostedmicewere challenged 28 days
later with either 19, 190, or 1,900 CFU of F. tularensis Schu S4 (Fig.
9A), and the boosted mice were challenged with either 190 or
1,900 CFU of F. tularensis Schu S4 (Fig. 9B). As can be seen in Fig.
9A and B, a single intranasal dose with the waaY::TrgTn strain
protected 1 of 5 mice challenged i.n. with 1,900 CFU of Schu S4, 1
of 5 mice challenged with 190 CFU of Schu S4, and 4 of 5 mice
challenged with 19 CFU of Schu S4. While this protection is sig-
nificant considering the extreme lethality of F. tularensis Schu S4
formice, boosting themicewith a second dose of thewaaY::TrgTn
mutant significantly increased the ability of the strain to elicit a
protective immune response to intranasal challenge with Schu S4.
FIG 8 Vaccination with Francisella tularensis waaY or waaLmutant provides protection against challenge with F. tularensis Schu S4. Groups of 5 BALB/c mice
were initially infected with three doses, from 102 to 104 CFU, of F. tularensis waaY::TrgTn or F. tularensis waaL::TrgTn. At 14 days postinfection (DPI), mice were
rechallenged with 5  105 CFU of the same strain. Twenty-eight days later, F. tularensis waaY::TrgTn-infected mice were challenged intraperitoneally with F.
tularensis Schu S4 (A), and F. tularensis waaL::TrgTn-infected mice were challenged intranasally with F. tularensis Schu S4 (B). Mice were tracked for 14 days for
signs of disease.
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The boosting of mice protected 2 of 5 mice (40%) challenged i.n.
with 190 CFU of Schu S4 and 3 of 5 mice (60%) challenged i.n.
with 1,900 CFU of Schu S4. These levels of protection are compa-
rable to those observed in the experiment described for Fig. 8 and
provide evidence that mice may be able to develop a memory
immune response when infected with these F. tularensis mutant
strains. The response that is elicited provides protection against
virulent F. tularensis Schu S4 challenge, which is a significant step
forward both in understanding the host response to Francisella
infection and in efforts to develop effective biotherapeutics.
DISCUSSION
In this work, we identified F. tularensis Schu S4 mutants that are
defective in capsule production with the goal of elucidating the
role of the Francisella capsule in the virulence strategy of this or-
ganism. This genetic screen identified 10 strains that represent 7
different genes that are defective for capsule production and have
altered LPS structures as well. Since two of these capsule-deficient
mutants were previously identified by our research group as de-
fective for growth in human macrophages, we carried out more
extensive characterization of the F. tularensis Schu S4 FTT1236
and FTT1238c genes, as well as the FTT1237 gene, which compose
a locus on the chromosome. Analysis of the translation products
of these genes revealed that they are similar toWaa gene products
that are involved in LPS biosynthesis inGram-negative bacteria by
performing the specific functions of adding sugars to the core
structure of LPS (WaaY andWaaZ) or adding O-antigen subunits
to the lipid A-core structure (WaaL). Interestingly, a fourth gene
in the same region, FTT1235c, encodes a product that is similar to
the mannosyltransferase LpcC as well as the glycosyltransferase
WaaG. This protein is predicted to add the first mannose of the
core to 3-deoxy-D-manno-octulosonic acid (Kdo). As we previ-
ously reported, we have been unable to make a mutant in
FTT1235c, as the mutation appears to be lethal (25). The specific
functions of WaaB, WaaI, and WaaJ are known for E. coli and
Salmonella species. In those species, WaaB adds a galactose as a
branch sugar to a core backbone glucose, whileWaaI andWaaJ are
responsible for adding a single hexose to the backbone, in concert
FIG 9 Intranasal vaccination and boosting of BALB/cmicewith F. tularensis waaY::TrgTn provide significant protection against challengewith F. tularensis Schu
S4. (A and B) Five groups of BALB/cmice were inoculated intranasally with 675CFUof F. tularensis waaY::TrgTn. (B) Two groups ofmice were boostedwith 500
CFU of F. tularensis waaY::TrgTn 14 days after the initial infection. Twenty-eight days later, the boosted and unboosted mice were challenged intranasally with
F. tularensis Schu S4, and the mice were tracked for 14 days for signs of disease. A group of naive mice were infected with 19 CFU of F. tularensis Schu S4 as an
infection control.
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(40). Interestingly, Francisella tularensis does have a galactose de-
rivative (galactosamine) as a branch core sugar (13). Additionally,
as mentioned previously, WaaL ligates polymerized O-antigen
units to the complete core of lipid A (40).
Since our sequence analysis indicated that the mutated Franci-
sella genes were likely involved in LPS biosynthesis, we per-
formed functional complementation experiments to examine
whether the F. tularensis waaY (FTT1236), waaZ (FTT1237), or
waaL (FTT1238c) gene had the ability to complement LPS biosyn-
thesis defects in E. coli strains (E. coli waaB or E. coli waaJmutant)
or a Salmonella strain (S. enterica waaL mutant). Due to the low
sequence similarity between these Francisella genes and the E. coli
and Salmonella genes, as well as the specific sugar reactions cata-
lyzed by these enzymes, there seemed to be a low probability that
we would observe any functional complementation in these ex-
periments. Surprisingly, however, each of the Francisella genes of
interest did modify core structures of E. coli or Salmonella waa
mutant strains, although the complementation was only partial in
each instance.
As another approach to investigate the functions of these Fran-
cisella genes, we examined the core structures and O-antigen lad-
dering of the LPS species of the mutants following carbohydrate
staining of electrophoretically separated preparations. These ex-
periments revealed that each of the mutants had detectable alter-
ations in LPS core biosynthesis compared to the F. tularensis Schu
S4 purified LPS. The F. tularensis waaY (FTT1236)mutant had the
most truncated core, and the core of the F. tularensis waaZ
(FTT1237) mutant was slightly larger than the core of the waaY
mutant. The F. tularensis waaL (FTT1238c) mutant appeared to
have a core structure similar in size to that of the F. tularensis Schu
S4 parent but lacked the O-antigen repeating units.
Mass spectrometric analyses further confirmed that the waaL
and waaY mutants had truncated LPS structures. The waaY mu-
tant expressed an LPSwith a truncated core structure consisting of
1 mannose (Man), 1 glucose (Glc), and 2 KDO residues. Compo-
sition and mass spectrometric analyses suggested that the waaL
mutant expressed a full core structure consisting of GalNAc, 2
Man residues, 2 Glc residues, and 2 KDO residues. Although our
predicted Francisella core structure contains two KDO sugars in-
stead of one KDO as previously reported by Vinogradov et al. (14,
42), ketosidic bonds are known to be labile, and this discrep-
ancy is most likely due to the isolation and processing of the
LPS prior to analyses. Additionally, the previously published
lipid A structure from this group identified a lipid A which
lacked the addition of any phosphate groups (14). Both in the
present study and in previous studies by us and others, the
predominant Francisella lipid A structure has been identified as
being monophosphorylated. This phosphate group can also be
substituted further with a galactosamine (13, 44). In the previous
study by Vinogradov et al., neither of these additions to the lipid A
structure were identified, lending further support to the possibil-
ity of the loss of labile groups in the processing of LPS (14). In fact,
this group even suggested the possibility of the loss of some con-
stituents due to the harsh conditions used for deacylation of the
structure (14).
The presence of free lipid A in the LPS samples made analyses
of the LPSmore challenging. The chloroform-methanol-water ex-
traction of the LPS samples improved the signal strength of the
LPS from LVS 0708::TrgTn but was not enough to improve the
MS signal intensity of LVS 0706::TrgTn LPS to detectable levels. In
a previous study byWang et al., it was estimated that less than 5%
of the total lipid A is linked to LPS (44). The presence of such a
large amount of free lipid A most likely contaminated the LPS
samples, making characterization of the structures significantly
more difficult.
The predominant Francisella LPS structure observed in vitro in
the virulent 1547-57 strain lacks free phosphate moieties and pro-
duces LPS with two 16- and two 18-carbon acyl groups instead of
six 14-carbon acyl groups (13). Importantly, some or all of these
differences produce LPS with a very low endotoxic activity. Syn-
thesis of LPS begins with the Lpx proteins, which synthesize and
assemble the lipid Amolecule (45), and initial transport of lipid A
is carried out by LptB and ValA (46, 47). Completion of lipid A
transport to the outermembrane is performed by LptA, LptD, and
RplB (48–50). Initial E. coli core sugar assembly mutants were
designated rfa (rough A) because the mutants grew with rough
colony phenotypes (40).We noticed in the course of workingwith
our F. tularensis mutants in FTT1236, FTT1237, and FTT1238c
that each strain produced colonies on agar that were significantly
rougher than those of the parental Schu S4 strain and that pos-
sessed altered colony consistency. In addition, electron micros-
copy of individual organisms indicated a significantly altered ap-
pearance (see Fig. S1 in the supplemental material). Together,
these observations provide additional evidence of the role of these
genes in LPS core assembly. As shown in Fig. 10, the products of
this biosynthetic pathway are ligated to polymerized O-antigen
subunits (51), which are synthesized by several proteins, including
WbaP/PNPTs, Wzx, and Wzy, which carry out the functions of
sugar synthesis, flipping, and polymerization of reaction interme-
diates to make the final O-antigen subunits available to be added
to the lipid A-core sugar structure (52–55) (Fig. 10).
Our results provide evidence that the Francisella gene products
ofwaaY,waaZ, andwaaLperform functions similar to those of the
waa gene products of other organisms (i.e., E. coli and Salmo-
nella). We found that an F. tularensis strain carrying a waaL mu-
tation has lipid A and a complete core but lacks O antigens. We
also present data showing that mutation of waaY results in the
most truncated lipid A-core structure, while mutation of waaZ
results in an intermediary structure that is larger than that ofwaaY
but smaller than the intact core structure observed in the waaL
mutant strain. These data establish that the proper biosynthesis of
the Francisella LPS core is critical for the addition of O-antigen
polymerized subunits to lipid A-core structures as well as for
proper assembly of the capsule structure. This suggests that full-
length LPS functions as a scaffold for capsule or that there is an
interaction between LPS and capsule that is necessary for outer
membrane capsular presence.
We have demonstrated that the Francisella waaY and waaL
genes contribute to the interactions of F. tularensis with the mu-
rine host. For mouse infection by the intraperitoneal route, the
LD50 of the waaYmutant was 7.6 10
6 CFU, and the LD50 of the
waaLmutant was 3.8 105 CFU, in contrast to the LD50 of Schu
S4, which is1 CFU. We believe that this attenuation of i.p. vir-
ulence is most likely due to the serum sensitivity of these mutant
strains (25). The difference in the LD50 values of the mutants
(1.3  104 CFU for the waaY mutant and 3  103 CFU for the
waaL mutant) and the Schu S4 parent (	10 CFU) for the intra-
nasal route of infection was significantly smaller than that ob-
served i.p. A precise explanation for this disparity is unknown, but
it seems likely to be due to either lower effective concentrations of
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serum in the lung or a highly efficient mechanism possessed by
Francisella to avoid the killing action of serum in the lung in order
to find a favorable intracellular growth niche, perhaps within al-
veolar macrophages and epithelial and/or endothelial lung cells.
The organ burden data acquired for the mutant strains, as a func-
tion of time postinfection, indicate that these strains can dissem-
inate and growwithin themurine host, although their growth rate
is significantly reduced compared to that of Schu S4. A possible
explanation for this difference may be the serum sensitivity of the
mutants or that induction of early death of the host cell limits
growth (25). In summary, the results from our virulence studies
with mice demonstrate that the activities of the products of the
waaY and waaL genes contribute to both the immune avoidance
and high virulence observed in the F. tularensis Schu S4 strain, as
these mutants are clearly more inflammatory in mice, based upon
pathological evidence, and have reduced virulence by both intra-
peritoneal and intranasal routes of infection.
Other researchers have looked at the value of using bacterial
mutants in rfaJ (waaJ) or rfaL (waaL) as potential vaccine strains.
BALB/c mice infected with either a Salmonella enterica rfaJ or rfaL
mutant showed significant protection from lethal challenge with a
virulent Salmonella strain (56). Billips et al. also demonstrated
that awaaLmutant in a uropathogenic strain of E. coliwas able to
provide protection against a broad range of uropathogenic isolates
of E. coli (57). In this work, we present data indicating that mice
infected intraperitoneally with the F. tularensis Schu S4waaLmu-
tant show protection against a lethal challenge with WT Schu S4.
We showed that 80% of mice survived an intranasal challenge of
2,000 CFU, while all mice survived a challenge of 200 CFU. Addi-
tionally, mice infected either intraperitoneally or intranasally with
the F. tularensis Schu S4 waaY mutant showed partial protection
against lethal intraperitoneal and intranasal challenges with WT
Schu S4, and a boost with the mutant essentially increased the
protection observed 10-fold. Recently, another group also dem-
onstrated that a Francisella strain that has modified LPS is able to
provide protection against a lethal Schu S4 challenge (58). These
data are very encouraging and provide the basis for future exper-
iments to explore the possibility of creating a useful therapeutic
against virulent strains of F. tularensis.
In summary, we have further characterized F. tularensis mu-
tants that we first demonstrated were unable to grow in human
MDMs (25). We confirmed that they do not produce capsule and
that they have altered LPS structures. We have provided experi-
mental data indicating that these mutations alter the synthesis of
the core sugar structures (waaY and waaZ) or the addition of O
antigen (waaL). Virulence studies in mice demonstrated signifi-
cant attenuation of virulence by both the i.p. and i.n. routes of
infection, and pathology studies indicated that the murine re-
sponse to infection with these mutants is significantly different
from that to the parent F. tularensis Schu S4 strain.We believe that
these studies provide compelling evidence to investigate the im-
mune response to these attenuated strains as part of our larger
effort to understand how virulent Francisella strains avoid im-
mune detection in a mammalian host and to understand in more
detail the unique virulence strategy of these highly pathogenic
bacteria.
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